ClinicalTrials.gov

History of Changes for Study: NCT03008148
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Latest version (submitted May 10, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 December 28, 2016 None (earliest Version on record)
2 January 2, 2017 Study Status and Contacts/Locations
3 January 8, 2020 Recruitment Status, Study Status, Oversight, Contacts/Locations, Outcome Measures, Arms and Interventions, Eligibility and Study Design
4 May 6, 2020 Study Status
5 July 21, 2020 Study Status
6 December 29, 2020 Contacts/Locations and Study Status
7 May 10, 2021 Study Status
Comparison Format:

Scroll up to access the controls

Study NCT03008148
Submitted Date:  December 28, 2016 (v1)

Open or close this module Study Identification
Unique Protocol ID: JP001-GM-001
Brief Title: Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Official Title: Randomized Phase II/III Trial of Radiotherapy Plus Concomitant and Adjuvant Temozolomide With or Without Hydroxychloroquine, Rapamycin for Newly Diagnosed Glioblastoma
Secondary IDs:
Open or close this module Study Status
Record Verification: December 2016
Overall Status: Not yet recruiting
Study Start: April 2017
Primary Completion: October 2023 [Anticipated]
Study Completion: October 2023 [Anticipated]
First Submitted: December 23, 2016
First Submitted that
Met QC Criteria:
December 28, 2016
First Posted: January 2, 2017 [Estimate]
Last Update Submitted that
Met QC Criteria:
December 28, 2016
Last Update Posted: January 2, 2017 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Johnpro Biotech, Inc.
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This is a multi-center, phase II/III, open-label, randomized, parallel and standard chemoradiation-controlled study where eligible subjects will be randomized at 1:1 ratio to receive control treatment or study treatment. The primary objective of this trial is to evaluate the effect of add-on JP001 to standard chemoradiation in increasing overall survival (OS) on newly diagnosed glioblastoma (GBM) patients.
Detailed Description: After enrollment, subjects' previous tumor block used for glioblastoma diagnosis that is consented to provide during the study period will be sent to a central laboratory for the assessment of MGMT status. Moreover, subjects will be randomized in either Control or Study arm at Visit 2. Subjects in Control arm will receive a standard chemoradiation. However, subjects in Study arm will receive a standard chemoradiation in combination with concurrent JP001 in whole study period. During the study, a sufficient amount of investigational products will be supplied to subjects in study groups until next scheduled visits. Subjects will self-administer investigational product orally with water at approximately the same time in each day. Subjects should fast for a minimum of 2 hours prior to any doses of JP001 and/or Temozolomide and then fast for another 1 hour after taking JP001 and/or Temozolomide. During and at the end of treatment, subjects will be evaluated for efficacy and safety parameters. Moreover, there will be a Follow-up visit for safety 4 weeks after the End-of-Treatment visit. If a subject is early withdrawn from the study, the End-of-Treatment visit should be arranged and all assessments assigned in this visit should be performed. The Safety Follow-up visit for early withdrawn subjects could be either clinic visit or telephone contact. If withdrawn subjects refuse to perform Follow-up visit, the Follow-up visit is allowed to cancel. For subjects who completed or discontinued study treatment, assessment of survival status will be performed every 8 weeks by telephone contact until death, study end (last subject last visit; the last subject needs to be followed at least 30 months), or study termination by Sponsor. Survival information will be recorded in the medical source and CRF. If subjects are lost to follow-up or refuse to receive the assessment of survival status, the investigator will record the last date subjects known to be alive in the medical source and case report form.
Open or close this module Conditions
Conditions: Glioblastoma
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2/Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 264 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Active Comparator: Radiation,Temozolomide
  1. CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
  2. Rest Phase: Rest for 4 weeks.
  3. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
  4. Maintenance Phase: No maintenance treatment until disease progression confirmed.
Radiation: CCRT
CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
Drug: Temozolomide
Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
Other Names:
  • Chemotherapy
Experimental: Radiation,Temozolomide,Siroquine(JP001)
  1. CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).
  2. Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.
  3. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).
  4. Maintenance Phase: JP001(2 tablets once a day) for 48 weeks until disease progression confirmed.
Radiation: CCRT
CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
Drug: Temozolomide
Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
Other Names:
  • Chemotherapy
Drug: Siroquine
  1. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).
  2. Maintenance Phase: JP001(2 tablets once a day) for 48 weeks until disease progression confirmed.
Other Names:
  • JP001
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Overall survival time.
[ Time Frame: 120 weeks ]

Secondary Outcome Measures:
1. Progression-free survival time
[ Time Frame: 120 weeks ]

2. OS rate at 1 year.
[ Time Frame: 1 year ]

3. PFS rate at 1 year.
[ Time Frame: 1 year ]

4. The time and rate of OS in different RPA class.
[ Time Frame: 120 weeks ]

5. The time and rate of PFS in different RPA class.
[ Time Frame: 120 weeks ]

6. Objective response rate.
[ Time Frame: 120 weeks ]

7. Changes in score of EORTC QLQ-C30
[ Time Frame: 120 weeks ]

8. Changes in score of EORTC QLQ-BN20.
[ Time Frame: 120 weeks ]

9. Changes in grade of ECOG performance status.
[ Time Frame: 120 weeks ]

Open or close this module Eligibility
Minimum Age: 20 Years
Maximum Age: 80 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  1. Subjects with histologically proven newly diagnosed case of GBM (WHO grade IV) and treatment-naive (chemotherapy and radiotherapy) for GBM. Diagnosis must be made by stereotactic biopsy or surgical excision, either partial or complete within 3 months prior to Visit 1.
  2. Subject's RPA class is class III, IV or V.
  3. Subjects with stereotactic biopsy or brain surgery must be suited for or will be scheduled for CCRT followed by Temozolomide treatment, the standard treatment recommended by institutes and fulfilled the reimbursement guideline of National Health Insurance Administration.
  4. Subjects must have recovered from the effects of surgery, post-operative infection, and other complications prior to Visit 1. Study treatment must be performed > 3 weeks and ≤ 8 weeks after craniotomy. Ventricular fluid reservoir or Ventriculo-Peritoneal shunting tube is allowed to keep.
  5. A diagnostic contrast-enhanced MRI of the brain must be performed postoperatively within 28 days prior to Visit 2 (Day 1).
  6. ECOG performance status ≤ 3 at Visit 1.
  7. Age from 20 to 80 years old at Visit 1.
  8. Life expectation ≥ 12 weeks at Visit 1.
  9. CBC/differential obtained at Visit 1, with adequate bone marrow function defined as follows:
    1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3 (1.5 x 109/L) or white blood cell (WBC) ≥ 3,000 cells/mm3 (3 x 109/L).
    2. Platelets count ≥ 100,000 cells/mm3 (100 x 109/L).
    3. Hemoglobin (Hgb or Hb) ≥ 10.0 g/dL (100 g/L) (Note: The use of transfusion or other intervention to achieve Hemoglobin ≥ 10.0 g/dL (100 g/L) is acceptable).
  10. Adequate renal function, as defined below:

    a. Creatinine ≤ 1.5 times upper laboratory limit at Visit 1.

  11. Adequate hepatic function, as defined below:
    1. Total Bilirubin ≤ 2.0 mg/dL (34.20 umol/L) at Visit 1.
    2. ALT ≤ 3 times upper laboratory limit at Visit 1.
    3. AST ≤ 3 times upper laboratory limit at Visit 1.
  12. For subjects with positive HBsAg, they must be taking Baraclude 0.5-1 mg once per day from Visit 1 or Visit 2.
  13. Subjects is able to understand and willing to comply with the study procedures and has signed the informed consent form (ICF).

Exclusion Criteria:

  1. Other invasive malignancy. However, subject with other invasive malignancy that have been disease-free more than or equal to 10 years and deemed no need for anti-cancer treatments can be recruited. Subjects with noninvasive malignancy, including carcinoma in situ of the breast, non-melanomatous skin cancer and cervix carcinoma in situ can be recruited if disease-free and treatment free more than or equal to 3 years.
  2. Metastases detected beyond the cranial vault.
  3. Subjects with the following history:
    1. Brain irradiation or Temozolomide usage.
    2. Macular degeneration or retinopathy.
    3. Renal transplantation.
  4. Subjects are currently receiving any anti-rejection medicine or Hydroxychloroquine sulfate for rheumatoid arthritis.
  5. Subjects with severe and active co-morbidity, defined as follows:
    1. Clinical active kidney, liver, lung or cardiac disease.
    2. Acute bacterial or fungal infection requiring intravenous antibiotics at Visit 1 and acquired immune deficiency syndrome (AIDS).
  6. Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant from study drug.
  7. Mean QTc > 500 msec (with Bazett's correction), history of familial long QT syndrome or other significant ECG abnormality noted at Visit 1.
  8. Known hypersensitivity reactions to Temozolomide, dacarbazine (DTIC), hydroxychloroquine, 4-aminoquinoline, rapamune, sirolimus, rapamycin, or their analogs.
  9. Women of child-bearing potential or men who are able to father a child unwilling to use a. medically acceptable method of contraception during the trial.
  10. Subjects participated in another investigational agent study in the past 30 days or are planning to do so during the study period.
  11. Subjects are considered ineligible for the study as judged by the investigator.
Open or close this module Contacts/Locations
Central Contact Person: Samuel Wang
Telephone: 886-925-297763
Email: yusam.wang@gmail.com
Central Contact Backup: Susan Huang
Telephone: 886-2-28332211 Ext. 2612
Email: susan.huang@johnpro.com.tw
Locations: Taiwan
Taipei Veterans General Hospital
Taipei City, Taiwan, 11217
Contact:Principal Investigator: Yu-Ming Liu, Ph.D.
Tri-Service General Hospital
Taipei City, Taiwan, 11490
Contact:Principal Investigator: Hsin-I Ma, Ph.D.
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services